Companies Dominating the Biologics CDMO Landscape
- AGC Biologics
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biocon Biologics Ltd.
- Catalent, Inc.
- Emergent BioSolutions
- JRS PHARMA LP
- Lonza Group Ltd.
- Binex Co., Ltd.
- Thermo Fisher Scientific Inc.
- Icon PLC
- Parexel International Corporation
Browse Key Market Insights with Data Illustration:
In the News
- At its protein biologics manufacturing facility in Seattle, AGC Biologics, a preeminent worldwide Biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), has announced the launch of a new commercial manufacturing project. Provention Bio, Inc., a biopharmaceutical firm dedicated to furthering the development of investigational medicines that may intercept and prevent debilitating and life-threatening immune-mediated disorders, is the source of TZIELD (teplizumab-mzwv), a novel medication for Type 1 Diabetes that the CDMO is creating.
- Being the first provider of biosimilar insulins to endorse and support the International Diabetes Federation (IDF) and its Core Mission initiative, Biocon Biologics Ltd. is a fully integrated, "pure play" biosimilars firm and a subsidiary of Biocon Ltd. This significant collaboration with IDF advances Biocon Biologics' goal of providing diabetics with accessible, inexpensive insulins on a global scale and aligns with the beginning of the centenary celebrations of insulin invention.
